Achromatopsia - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Achromatopsia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Achromatopsia - Pipeline Review, H1 2016', provides an overview of the Achromatopsia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Achromatopsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Achromatopsia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Achromatopsia
- The report reviews pipeline therapeutics for Achromatopsia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Achromatopsia therapeutics and enlists all their major and minor projects
- The report assesses Achromatopsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Achromatopsia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Achromatopsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Achromatopsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Achromatopsia Overview 7
Therapeutics Development 8
Pipeline Products for Achromatopsia - Overview 8
Achromatopsia - Therapeutics under Development by Companies 9
Achromatopsia - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Achromatopsia - Products under Development by Companies 12
Achromatopsia - Companies Involved in Therapeutics Development 13
Amgen Inc. 13
Applied Genetic Technologies Corporation 14
Achromatopsia - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Drug Profiles 19
Gene Therapy for Achromatopsia - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gene Therapy for X-linked retinoschisis and Achromatopsia - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy to Activate CNGA3 for Achromatopsia - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Gene Therapy to Activate CNGB3 for Achromatopsia - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Gene Therapy to Activate Cone Photoreceptor cGMP-Gated Channel for Achromatopsia - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NT-501 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Achromatopsia - Recent Pipeline Updates 28
Achromatopsia - Product Development Milestones 32
Featured News & Press Releases 32
Apr 20, 2016: AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia 32
Jan 07, 2016: AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases 33
Nov 23, 2015: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia 34
Nov 02, 2015: AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGB3 Gene 34
Oct 22, 2015: AGTC Announces Orphan Drug Designation in the European Union for Gene Therapy to Treat Achromatopsia 35
Aug 27, 2015: AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration 35
May 18, 2015: AGTC Announces New Data Supporting Novel Gene-Based Therapies for Rare Inherited Retinal Diseases 36
May 04, 2015: Novel Gene-Based Therapy for Achromatopsia Demonstrates Functional Rescue of Cone Cells 37
Jul 23, 2013: The University of Florida and AGTC Secure $8.4M Grant to Study Rare Eye Disease 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables

Number of Products under Development for Achromatopsia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Achromatopsia - Pipeline by Amgen Inc., H1 2016 13
Achromatopsia - Pipeline by Applied Genetic Technologies Corporation, H1 2016 14
Assessment by Monotherapy Products, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 18
Achromatopsia Therapeutics - Recent Pipeline Updates, H1 2016 28